Clozapine dosages and plasma drug concentrations

Journal of the Formosan Medical Association

Volumn 96, Issue 8, 1997, Pages 599-605

  Chang, Wen Ho ^a,b,c   Lin, Shih Ku ^a,c   Lane, Hsien Yuan ^a,d   Hu, Wei Herng ^a,c   Jann, Michael W ^e   Lin, Hsin Nan ^a,b  

^a NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^c TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^d NATIONAL DEFENSE MEDICAL CENTER   (Taiwan)

^e MERCER UNIVERSITY   (United States)

Author keywords

Clozapine; Plasma concentrations; Refractory schizophrenia; Therapeutic drag monitoring

Indexed keywords

CLOZAPINE; CLOZAPINE N OXIDE; DRUG METABOLITE; NORCLOZAPINE; UNCLASSIFIED DRUG;

ADULT; ARTICLE; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG MONITORING; DRUG RESISTANCE; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MAJOR CLINICAL STUDY; MALE; PREDICTION; SCHIZOPHRENIA; SEIZURE; STEADY STATE;

ADULT; AGED; ANTIPSYCHOTIC AGENTS; CLOZAPINE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; MALE; MIDDLE AGED;

EID: 0030825718     PISSN: 09296646     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. Jann MW, Grinsley SR, Gray EC, et al: Pharmacokinetics and pharmacodynamics of clozapine. Clin Pharmacokinet 1993;24:161-76.
2. Jann MW, Lam YWF, Chang WH: Rapid formation of clozapine in guinea pigs and man following clozapine-N-oxide administration. Arch Intern Pharmacodyn Ther 1994;328:243-50.
3. Chang WH, Lin SK, Lane HY, et al: Reversible metabolism of clozapine and clozapine-N-oxide. Eur Neuropsychopharmacol 1996;6:39. [Abstract]
4. Jann MW, Lam YWF, Gray EC, et al: Reversible metabolism of drugs. Drug Metab Drug Interact 1994;11:1-24.
5. Yang TT, Chen PM, Tai YM, et al: The evaluation of clinical effects of clozapine on chronic treatment-resistant schizophrenic patients. Chin Psychiatry 1993;7:223-33. [in Chinese; English abstract]
6. Liu HC, Wei FC, Lin SK, et al: Plasma clozapine concentration and treatment response in refractory schizophrenic patients. Chin Psychiatry 1995;9:274-82. [in Chinese; English abstract]
7. Lin SK, Chang WH, Chung MC, et al: Disposition of clozapine and desmethylclozapine in schizophrenic patients. J Clin Pharmacol 1994;34:318-24.
8. Liu HC, Chang WH, Wei FC, et al: Monitoring of plasma clozapine levels and its metabolites in refractory schizophrenic patients. Ther Drug Monit 1996;18:200-7.
9. Perry PJ, Miller DD, Arndt SV, et al: Clozapine and norclozapine plasma concentrations and clinical response of treatment-resistant schizophrenic patients. Am J Psychiatry 1991;148:231-5.
10. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, 3rd ed. revised. Washington, DC: American Psychiatric Association, 1987
11. Kane JM, Honigfeld G, Singer J, et al: Clozapine for the treatment-resistant schizophrenic: a double-blind comparison with chlorpromazine. Arch Gen Psychiatry 1988;45:79-96.
12. Jerling M, Lindstrom L, Bondesson U, et al: Fluvoxamine inhibition and carbamazepine induction of the metabolism of clozapine: evidence from a therapeutic drug monitoring service. Ther Drug Monit 1994;16:368-74.
13. Weigmann H, Hiemke C: Determination of clozapine and its major metabolites in human serum using automated solid-phase extraction and subsequent isocratic high performance liquid chromatography with ultraviolet detection. J Chromatogr 1992;583:209-16.
14. Chung MC, Lin SK, Chang WH, et al: Determination of clozapine and desmethylclozapine in human plasma by high performance liquid chromatography with ultraviolet detection. J Chromatogr 1992;613:168-73.
15. Lane HY, Lin HN, Hwu HG, et al: Haloperidol plasma concentrations in Taiwanese psychiatric patients. J Formos Med Assoc 1995;94:671-8.
16. Gu NF, YinJL, Zhang C, et al: Pharmacokinetic study of clozapine. Chin J Neurol Psychiatry 1989;21:259-62. [in Chinese; English abstract]
17. Yu DS, Guo SZ, Wang WY, et al: The correlation between clozapine saliva level and clinical response as well as side effectin patient with schizophrenia. Chin J Neurol Psychiatry 1992;25:165-7. [in Chinese; English abstract]
18. Bondesson U, Lindstrom LH: Determination of clozapine and its N-demethylated metabolite in plasma by use of gas chromatography-mass spectrometry with single ion detection. Psychopharmacology 1988;95:472-5.
19. Meltzer HY: Treatment of the neurolepticnonresponsive schizophrenic patient. Psychopharmacol Bull 1992; 18:515-42.
20. Potkin SG, Bera R, Gulasekaram B, et al: Plasma concentrations predict clinical response in treatment-resistant schizophrenia. J Clin Psychiatry 1994;55:133-6.
21. Kronig MH, Munne RA, Szymanski DO, et al: Plasma clozapine levels and clinical response for treatment-refractory schizophrenic patients. Am J Psychiatry 1995;152:179-82.
22. Chang WH, Jann MW, Hwu HG, et al: Ethnic comparison of haloperidol and reduced haloperidol plasma levels: Taiwan Chinese versus American non-Chinese. J Formos Med Assoc 1991;90:572-8.
23. Van Putten TV, Marder SR, Wirhing WC, et al: Neuroleptic plasma levels. Schizophr Bull 1991;17:197-216.
24. Dahl ML, Bertilsson L: Genetically variable metabolism of antidepressants and neuroleptic drugs in man. Pharmacogenetics 1993;3:61-70.
25. Wang SL, Huang JD, Lai MD, et al: Molecular basis of genetic variation in debrisoquin hydroxylation in Chinese subjects: polymorphism in RFLP and DNA sequence of CYP2D6. Clin Pharmacol Ther 1993;53:410-8.
26. Lane HY, Deng HC, Huang SM, et al: Low frequency of dextromethorphan O-demethylation deficiency in a Chinese population. Clin Phamacol Ther 1996;60:696-8.
27. Bertilsson L, Carrillo JA, Dahl ML, et al: Clozapine disposition covaries with CVP 1A2 activity determined by a caffeine test. Br J Clin Pharmacol 1994;38:471-3.
28. CentorrinoFC, Baldessarni RJ, Kando JC, et al: Clozapine and metabolites: concentrations in serum and clinical findings during the treatment of chronically psychotic patients. J Clin Psychopharmacol 1994;14:119-25.
29. Dahl SG: Active metabolites of neuroleptic drugs: possible contribution to therapeutic and toxic effects. Ther Drug Monit 1982;4:33-40.
30. Chetty M, Moodley SV, Miller R: Important metabolites to measure in pharmacodynamic studies with chlorpromazine. Ther Drug Monit 1994;16:30-6.
31. Piscitelli SC, Frazier JA, McKema K, et al: Plasma clozapine and haloperidol concentrations in adolescents with childhood-onset schizophrenia: association with response. J Clin Psychiatry 1994;55:94-7.
32. Gershon SL, Meltzer HY: Mechanism of clozapine induced agranulocytosis. Drug Saf 1992;7:17-25.
33. Pickar D, Owen RR, Litman RE, et al: Clinical and biologic response to clozapine in patients with schizophrenia. Arch Gen Psychiatry 1992;49:345-53.
34. Centorrino F, Baldessarni RJ, Kando J, et al: Serum concentrations of clozapine and its major metabolites: effects of cotreatment with fluoxetine or valproate. Am J Psychiatry 1994;151:123-5.
35. Koponen HJ, Leinonen E, Lepola U: Fluvoxamine increases the clozapine serum levels significantly. Eur Neuropsychopharmacol 1996;6:69-71.
36. Brosen K, Skjelbo E, Rasmussen BB, et al: Fluvoxamine is a potent inhibitor of cytochrome P450 1A2. Biochem Pharmacol 1993;45:1211-4.
37. Szegedi A, Wiesner J, Hiemke C: Improved efficacy and fewer side-effects under clozapine treatment after addition of fluvoxamine J Clin Psychopharmacol 1995;15:141-3.
38. Vartiainen H, Tiihonen J, Pukunen A, et al: The selective serotonin re-uptake inhibitor, citalopram, in the treatment of aggression in schizophrenia. Acta Psychiatr Scand 1995;91:348-51.
39. Haller E, Binder RL: Clozapine and seizures. Am J Psychiatry 1990;147:1069-71.